Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 10.57
SUPN's Cash to Debt is ranked higher than
59% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. SUPN: 10.57 )
Ranked among companies with meaningful Cash to Debt only.
SUPN' s Cash to Debt Range Over the Past 10 Years
Min: 0.19  Med: 2.76 Max: No Debt
Current: 10.57
Equity to Asset 0.65
SUPN's Equity to Asset is ranked higher than
53% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. SUPN: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
SUPN' s Equity to Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.42 Max: 0.68
Current: 0.65
-2.25
0.68
Interest Coverage 30.17
SUPN's Interest Coverage is ranked lower than
59% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.24 vs. SUPN: 30.17 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 9.63 Max: N/A
Current: 30.17
F-Score: 5
Z-Score: 9.13
M-Score: -1.68
WACC vs ROIC
12.69%
37.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.40
SUPN's Operating margin (%) is ranked higher than
71% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. SUPN: 15.40 )
Ranked among companies with meaningful Operating margin (%) only.
SUPN' s Operating margin (%) Range Over the Past 10 Years
Min: -37851.89  Med: -403.06 Max: 27.1
Current: 15.4
-37851.89
27.1
Net-margin (%) 14.94
SUPN's Net-margin (%) is ranked higher than
80% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. SUPN: 14.94 )
Ranked among companies with meaningful Net-margin (%) only.
SUPN' s Net-margin (%) Range Over the Past 10 Years
Min: -36285.85  Med: -187.84 Max: 6701.74
Current: 14.94
-36285.85
6701.74
ROE (%) 21.75
SUPN's ROE (%) is ranked higher than
85% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. SUPN: 21.75 )
Ranked among companies with meaningful ROE (%) only.
SUPN' s ROE (%) Range Over the Past 10 Years
Min: -202.72  Med: -63.41 Max: 37.92
Current: 21.75
-202.72
37.92
ROA (%) 14.14
SUPN's ROA (%) is ranked higher than
88% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. SUPN: 14.14 )
Ranked among companies with meaningful ROA (%) only.
SUPN' s ROA (%) Range Over the Past 10 Years
Min: -90.03  Med: -21.41 Max: 106.84
Current: 14.14
-90.03
106.84
ROC (Joel Greenblatt) (%) 711.46
SUPN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.24 vs. SUPN: 711.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SUPN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4247.75  Med: -1920.51 Max: 711.46
Current: 711.46
-4247.75
711.46
Revenue Growth (3Y)(%) 221.40
SUPN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. SUPN: 221.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SUPN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 69 Max: 221.4
Current: 221.4
0
221.4
» SUPN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

SUPN Guru Trades in Q3 2015

Paul Tudor Jones 33,600 sh (+34.94%)
Jim Simons 125,100 sh (+8.78%)
Robert Bruce 394,581 sh (-43.19%)
Joel Greenblatt 39,142 sh (-55.66%)
» More
Q4 2015

SUPN Guru Trades in Q4 2015

Paul Tudor Jones 47,000 sh (+39.88%)
Jim Simons Sold Out
Joel Greenblatt 33,808 sh (-13.63%)
Robert Bruce 254,581 sh (-35.48%)
» More
Q1 2016

SUPN Guru Trades in Q1 2016

Steven Cohen 944,746 sh (New)
Robert Bruce 224,581 sh (-11.78%)
Joel Greenblatt 17,552 sh (-48.08%)
Paul Tudor Jones 20,300 sh (-56.81%)
» More
Q2 2016

SUPN Guru Trades in Q2 2016

Robert Bruce 224,581 sh (unchged)
Paul Tudor Jones 14,500 sh (-28.57%)
Joel Greenblatt 12,455 sh (-29.04%)
Steven Cohen 35,600 sh (-96.23%)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:LCI, NAS:EGRX, NAS:SGYP, NAS:DEPO, NAS:CPXX, NAS:AMPH, OTCPK:KHTRF, NAS:MNTA, NAS:HRTX, NAS:ACET, NAS:SGNT, OTCPK:LPCUF, OTCPK:EVTCY, NAS:PCRX, NAS:LBIO, NAS:SCMP, NAS:SCLN, NAS:FLXN, NAS:IPXL, NAS:INNL » details
Traded in other countries:S49.Germany,
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc was incorporated in Delaware on March 30, 2005. The Company is a specialty pharmaceutical company engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has other proprietary product candidates in clinical development that address the psychiatry market. The Company is developing multiple product candidates in psychiatry to address the unmet medical needs and market opportunities in impulsive aggression across several areas including attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder, and ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR. Oxtellar XR is indicated for adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age and Trokendi XR is indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures or with seizures associated with Lennox-Gastaut syndrome. Its psychiatry product candidates include ADHD, SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). ADHD is a common CNS disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity; and it develops SPN-810 (molindone hydrochloride) as a treatment for impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment. The Company has a portfolio of drug development technologies consisting of platforms including Microtrol, Solutrol and EnSoTrol. It is utilized to create nine marketed products, including Trokendi XR and Oxtellar XR, as well as other product candidates SPN-810 and SPN-812. The Company markets its products in the United States through its specialty sales force. The Company is subject to regulation by FDA, federal and state government authorities. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.

Ratios

vs
industry
vs
history
P/E(ttm) 46.95
SUPN's P/E(ttm) is ranked lower than
72% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. SUPN: 46.95 )
Ranked among companies with meaningful P/E(ttm) only.
SUPN' s P/E(ttm) Range Over the Past 10 Years
Min: 0.13  Med: 43.42 Max: 91.17
Current: 46.95
0.13
91.17
PE(NRI) 46.95
SUPN's PE(NRI) is ranked lower than
72% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.53 vs. SUPN: 46.95 )
Ranked among companies with meaningful PE(NRI) only.
SUPN' s PE(NRI) Range Over the Past 10 Years
Min: 16.59  Med: 45.76 Max: 91.17
Current: 46.95
16.59
91.17
Price/Owner Earnings (ttm) 48.03
SUPN's Price/Owner Earnings (ttm) is ranked lower than
62% of the 278 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.03 vs. SUPN: 48.03 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SUPN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 19.48  Med: 37.74 Max: 188.33
Current: 48.03
19.48
188.33
P/B 7.74
SUPN's P/B is ranked lower than
86% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. SUPN: 7.74 )
Ranked among companies with meaningful P/B only.
SUPN' s P/B Range Over the Past 10 Years
Min: 3.23  Med: 6.81 Max: 18.53
Current: 7.74
3.23
18.53
P/S 6.49
SUPN's P/S is ranked lower than
73% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. SUPN: 6.49 )
Ranked among companies with meaningful P/S only.
SUPN' s P/S Range Over the Past 10 Years
Min: 3.21  Med: 7.9 Max: 103.29
Current: 6.49
3.21
103.29
PFCF 40.02
SUPN's PFCF is ranked lower than
68% of the 188 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. SUPN: 40.02 )
Ranked among companies with meaningful PFCF only.
SUPN' s PFCF Range Over the Past 10 Years
Min: 16.47  Med: 31.89 Max: 393.04
Current: 40.02
16.47
393.04
POCF 37.06
SUPN's POCF is ranked lower than
76% of the 249 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. SUPN: 37.06 )
Ranked among companies with meaningful POCF only.
SUPN' s POCF Range Over the Past 10 Years
Min: 16.14  Med: 29.41 Max: 244.32
Current: 37.06
16.14
244.32
EV-to-EBIT 36.90
SUPN's EV-to-EBIT is ranked lower than
75% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.84 vs. SUPN: 36.90 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -402.1  Med: -2.1 Max: 71.3
Current: 36.9
-402.1
71.3
EV-to-EBITDA 34.91
SUPN's EV-to-EBITDA is ranked lower than
76% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.38 vs. SUPN: 34.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4453.5  Med: -2.1 Max: 67.2
Current: 34.91
-4453.5
67.2
Current Ratio 1.74
SUPN's Current Ratio is ranked lower than
65% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. SUPN: 1.74 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.94 Max: 7.26
Current: 1.74
1.51
7.26
Quick Ratio 1.49
SUPN's Quick Ratio is ranked lower than
60% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. SUPN: 1.49 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.71 Max: 7.26
Current: 1.49
1.49
7.26
Days Inventory 522.40
SUPN's Days Inventory is ranked lower than
98% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. SUPN: 522.40 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 522.4  Med: 652.7 Max: 1372.72
Current: 522.4
522.4
1372.72
Days Sales Outstanding 71.61
SUPN's Days Sales Outstanding is ranked higher than
54% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.29 vs. SUPN: 71.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 65.48 Max: 16387.12
Current: 71.61
2.71
16387.12
Days Payable 83.29
SUPN's Days Payable is ranked higher than
61% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.61 vs. SUPN: 83.29 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 83.29  Med: 186.94 Max: 1038.8
Current: 83.29
83.29
1038.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.00
SUPN's 3-Year Average Share Buyback Ratio is ranked lower than
79% of the 425 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. SUPN: -17.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SUPN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.2  Med: -17 Max: 0
Current: -17
-199.2
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 29.82
SUPN's Price/Net Current Asset Value is ranked lower than
88% of the 439 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SUPN: 29.82 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SUPN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.98  Med: 14.42 Max: 42.12
Current: 29.82
3.98
42.12
Price/Tangible Book 8.72
SUPN's Price/Tangible Book is ranked lower than
79% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. SUPN: 8.72 )
Ranked among companies with meaningful Price/Tangible Book only.
SUPN' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.86  Med: 6.73 Max: 19.49
Current: 8.72
3.86
19.49
Price/Median PS Value 0.82
SUPN's Price/Median PS Value is ranked higher than
77% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. SUPN: 0.82 )
Ranked among companies with meaningful Price/Median PS Value only.
SUPN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 1.08 Max: 10.21
Current: 0.82
0.41
10.21
Price/Graham Number 4.27
SUPN's Price/Graham Number is ranked lower than
78% of the 411 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.33 vs. SUPN: 4.27 )
Ranked among companies with meaningful Price/Graham Number only.
SUPN' s Price/Graham Number Range Over the Past 10 Years
Min: 2.37  Med: 3.58 Max: 4.47
Current: 4.27
2.37
4.47
Earnings Yield (Greenblatt) (%) 2.71
SUPN's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SUPN: 2.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SUPN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.4  Med: 3 Max: 10.5
Current: 2.71
1.4
10.5

More Statistics

Revenue (TTM) (Mil) $174.7
EPS (TTM) $ 0.47
Beta1.50
Short Percentage of Float5.41%
52-Week Range $9.51 - 24.00
Shares Outstanding (Mil)49.51
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 24 2016
Supernus' Trokendi XR Gets FDA Nod for Migraine in Adults Aug 22 2016
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine... Aug 19 2016
SUPERNUS PHARMACEUTICALS INC Financials Aug 16 2016
ETF’s with exposure to Supernus Pharmaceuticals, Inc. : August 16, 2016 Aug 16 2016
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III... Aug 12 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 12 2016
Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III... Aug 12 2016
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 05 2016
Edited Transcript of SUPN earnings conference call or presentation 3-Aug-16 1:00pm GMT Aug 03 2016
Supernus Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Aug 03 2016
Supernus tops 2Q profit forecasts Aug 02 2016
Supernus tops 2Q profit forecasts Aug 02 2016
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 02 2016
Supernus Announces Second Quarter 2016 Financial Results Aug 02 2016
Supernus Announces Second Quarter 2016 Financial Results Aug 02 2016
2 Biotech Funds Leading Nascent Bull Market: Which Is Right For You? Aug 02 2016
Q2 2016 Supernus Pharmaceuticals Inc Earnings Release - After Market Close Aug 02 2016
Are Biotechs Finally Making A Comeback? Here Are 5 Must-Watch Names Aug 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)